{"filing":{"accession_number":"0001628280-26-052170","cik":"0001649904","ticker":"RYTM","company_name":"RHYTHM PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"rytm-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/rytm-20260804.htm"},"events":[{"id":24026,"run_id":21733,"accession_number":"0001628280-26-052170","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.96,"summary":"Rhythm Pharmaceuticals announced its second quarter 2026 financial results on August 4, 2026, reporting net product revenue of $71.3 million, a net loss of $(50.4) million, and providing full-year 2026 financial guidance. The earnings release also included preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity showing an 11.6% mean BMI reduction at 16 weeks.","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24410,"accession_number":"0001628280-26-052170","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Rhythm Pharmaceuticals' second quarter 2026 financial results. The filing explicitly states \"On August 4, 2026, Rhythm Pharmaceuticals, Inc. (the 'Company') announced its financial results for the second quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1. The press release reports Q2 2026 net product revenue of $71.3 million, R\u0026D expenses of $43.4 million, SG\u0026A expenses of $67.4 million, and a net loss of $(50.4) million, along with year-to-date results and forward guidance. This is material to investors as it discloses the company's commercial performance and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:41.301611+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24411,"accession_number":"0001628280-26-052170","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces the issuance of a press release and presentation disclosing preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity. However, the supplemental exhibit (EX-99.1) is Rhythm Pharmaceuticals' second quarter 2026 earnings release, which reports Q2 2026 net product revenue of $71.3 million from IMCIVREE, year-to-date revenue of $131.4 million, detailed operating expenses, net loss of $(50.4) million for Q2, and full-year 2026 financial guidance. This is a comprehensive quarterly earnings disclosure with financial results, business updates, and forward guidance—the hallmark of an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:41.301611+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24412,"accession_number":"0001628280-26-052170","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on preliminary Phase 2 trial data for RM-718 in acquired hypothalamic obesity, showing an 11.6% mean BMI reduction at 16 weeks. However, the supplemental exhibit (EX-99.1) is a comprehensive earnings release reporting Q2 2026 financial results ($71.3M in IMCIVREE revenue), business updates, and forward guidance. While the Item 8.01 text itself focuses on clinical trial data, the filing's primary substance—as evidenced by the press release—is disclosure of quarterly financial results and business performance, making this fundamentally an earnings_release disclosure despite the Item 8.01 designation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:41.301611+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24410,"accession_number":"0001628280-26-052170","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Rhythm Pharmaceuticals' second quarter 2026 financial results. The filing explicitly states \"On August 4, 2026, Rhythm Pharmaceuticals, Inc. (the 'Company') announced its financial results for the second quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1. The press release reports Q2 2026 net product revenue of $71.3 million, R\u0026D expenses of $43.4 million, SG\u0026A expenses of $67.4 million, and a net loss of $(50.4) million, along with year-to-date results and forward guidance. This is material to investors as it discloses the company's commercial performance and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:41.301611+00:00","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-08-04"},{"id":24411,"accession_number":"0001628280-26-052170","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces the issuance of a press release and presentation disclosing preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity. However, the supplemental exhibit (EX-99.1) is Rhythm Pharmaceuticals' second quarter 2026 earnings release, which reports Q2 2026 net product revenue of $71.3 million from IMCIVREE, year-to-date revenue of $131.4 million, detailed operating expenses, net loss of $(50.4) million for Q2, and full-year 2026 financial guidance. This is a comprehensive quarterly earnings disclosure with financial results, business updates, and forward guidance—the hallmark of an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:41.301611+00:00","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-08-04"},{"id":24412,"accession_number":"0001628280-26-052170","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on preliminary Phase 2 trial data for RM-718 in acquired hypothalamic obesity, showing an 11.6% mean BMI reduction at 16 weeks. However, the supplemental exhibit (EX-99.1) is a comprehensive earnings release reporting Q2 2026 financial results ($71.3M in IMCIVREE revenue), business updates, and forward guidance. While the Item 8.01 text itself focuses on clinical trial data, the filing's primary substance—as evidenced by the press release—is disclosure of quarterly financial results and business performance, making this fundamentally an earnings_release disclosure despite the Item 8.01 designation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:41.301611+00:00","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-08-04"}]}